Which payload types can you formulate?

We work with mRNA, siRNA, antisense oligonucleotides, miRNA mimics and inhibitors, and plasmid DNA. Payload types outside this range can be discussed during scoping, because the appropriate vehicle and characterisation strategy differ substantially between payload classes.

Can you use our proprietary lipids or payloads?

Yes. Client-supplied lipids, polymers, and payloads are routinely incorporated into screening, and we can work under confidentiality terms with internal identifiers. Material requirements and minimum quantities are confirmed during scoping.

How do you assess whether a formulation actually delivers?

Particle properties alone do not demonstrate delivery, so we pair physicochemical characterisation with functional readouts such as expression, knockdown, or cellular uptake. That combination is what distinguishes a particle that forms from one that works.

Do you support scale-up and technology transfer?

We document critical process parameters and analytical methods so that your CMC group can reproduce the formulation. The scope of hands-on scale-up support is agreed during consultation and depends on the process and equipment involved.

What is the typical turnaround time?

Turnaround depends on the number of formulations screened, the assays involved, and payload availability. Please contact our team for a timeline specific to your program.

Services

Online Inquiry

Name *

Email *

Subject *

Phone

Your Message

How Did You Hear About Us

Advanced Drug Delivery & RNA Therapeutics

Delivery Systems & Nucleic Acid Therapeutics

Engineer lipid nanoparticles and conjugate chemistries that carry mRNA, siRNA, and antisense payloads to the intended tissue. We pair formulation science with the characterisation needed to advance a candidate.

Lipid nanoparticle and conjugate screening from discovery to candidate stage
Ionisable and helper lipid selection guided by pKa and tolerability
Physicochemical characterisation: size, PDI, zeta potential, encapsulation
In vitro potency and delivery readouts in relevant cell models

Start Your Project

Why Choose Our Delivery & RNA Team?

Formulation, characterisation, and biology sit in one team, so a delivery problem is diagnosed rather than guessed at.

Formulation scientists and analytical chemists working on the same bench
Screening platforms sized for both early discovery and candidate-stage work
Payload-agnostic experience across mRNA, siRNA, ASO, and plasmid DNA
Documented methods that transfer cleanly to your CMC group

Tunable

Targeted

Scalable

Our Approach

Formulation Built Around the Payload

Delivery fails for specific, measurable reasons. We characterise the payload, screen vehicles against the barriers you actually face, and iterate on composition until potency and stability are reproducible rather than incidental.

Delivery Vehicle Engineering

Screen and optimise lipid nanoparticles, lipoplexes, and conjugate systems against the delivery route you intend to use.

Ionisable lipid, helper lipid, sterol, and PEG-lipid ratio screening
Microfluidic and bulk mixing process parameters
Encapsulation efficiency and payload integrity assessment
Stability screening across defined storage conditions

RNA Payload Characterisation

Confirm that the payload survives formulation and reaches the cytosol intact before any potency claim is made.

mRNA integrity and capping efficiency assessment
siRNA duplex and antisense backbone integrity
In vitro potency with expression or knockdown readouts
Cellular uptake and endosomal escape assessment

Tunable

Composition and process parameters are screened systematically, so delivery is adjusted rather than accepted as given.

Targeted

Where extrahepatic delivery is required, targeting ligands and tropism are evaluated alongside the formulation itself.

Transferable

Methods and critical process parameters are documented so your CMC group can reproduce the formulation.

Deliverables

What You Receive

A formulation and characterisation package designed to be handed to a CMC or pharmacology group without rework.

Formulation Deliverables

Selected formulation composition with process parameters
Size, PDI, zeta potential, and encapsulation efficiency data
Payload integrity and stability results across tested conditions
Screening data for every candidate formulation evaluated

Reporting & Support

Formulation development report with the decision rationale
In vitro potency data with assay conditions and controls
Methods section suitable for manuscript or regulatory use
Technical consultation on scale-up and analytical transfer

Service Scope

Customizable Formulation Parameters

Every program is scoped individually after a consultation. The table below outlines typical parameters and options.

Parameter	Typical project scope
Payload Type	mRNA, siRNA, antisense oligonucleotide, miRNA mimic or inhibitor, or plasmid DNA
Delivery Vehicle	Lipid nanoparticles, lipoplexes, polymer nanoparticles, or ligand-conjugated systems
Lipid Components	Commercial lipid libraries or client-supplied ionisable and helper lipids screened at defined molar ratios
Formulation Process	Microfluidic mixing, bulk ethanol injection, or a client-specified process
Targeting Strategy	Passive hepatic accumulation or active targeting using ligand-decorated particles
Characterisation	Size, PDI, zeta potential, encapsulation efficiency, pH, and payload integrity
In Vitro Evaluation	Potency, knockdown or expression, cytotoxicity, and uptake in relevant cell models
Stability Assessment	Short-term physical and chemical stability across defined temperature and buffer conditions
Technical Support	Subject to customer service consultation

Workflow

From Payload to Reproducible Formulation

Our five-step process screens composition and process parameters against functional readouts, so the lead formulation is the one that works rather than the one that formed first.

Payload Characterisation

Assess the integrity, purity, and potency of the incoming mRNA, siRNA, or antisense payload before formulation begins.

Vehicle Selection

Shortlist lipid, polymer, or conjugate systems and targeting strategies against the intended route and target tissue.

Formulation & Screening

Prepare candidate formulations and screen composition and process parameters for particle properties and encapsulation.

In Vitro Evaluation

Test potency, uptake, and tolerability in relevant cell models to identify the leading candidates.

Optimisation & Transfer

Confirm reproducibility and stability of the lead, then document methods for scale-up and handover.

Applications

Programs We Support

Our formulation and characterisation workflows are applied across vaccine, RNAi, and targeted delivery programs.

Deliver Functional mRNA

Formulate mRNA into particles that protect the transcript, reach the target cell, and translate once inside, with integrity and capping confirmed at each step.

mRNA integrity and capping efficiency assessment
Ionisable lipid screening for transfection and tolerability
Expression readouts in relevant cell models

Reach the Target Transcript

Optimise duplex or backbone chemistry together with the delivery vehicle so that knockdown is achieved at tolerable doses.

Duplex and backbone integrity assessment
Knockdown potency with dose-response profiling
Cytotoxicity and innate immune readouts

Move Beyond the Liver

Evaluate targeting ligands and particle design for tissues where passive accumulation alone is not sufficient.

Ligand decoration and targeting evaluation
Uptake and delivery readouts in relevant models
Formulation adjustments for tissue-specific barriers

FAQ

Frequently Asked Questions

Common questions about our drug delivery and RNA therapeutics service.

We work with mRNA, siRNA, antisense oligonucleotides, miRNA mimics and inhibitors, and plasmid DNA. Payload types outside this range can be discussed during scoping, because the appropriate vehicle and characterisation strategy differ substantially between payload classes.
Yes. Client-supplied lipids, polymers, and payloads are routinely incorporated into screening, and we can work under confidentiality terms with internal identifiers. Material requirements and minimum quantities are confirmed during scoping.
Particle properties alone do not demonstrate delivery, so we pair physicochemical characterisation with functional readouts such as expression, knockdown, or cellular uptake. That combination is what distinguishes a particle that forms from one that works.
We document critical process parameters and analytical methods so that your CMC group can reproduce the formulation. The scope of hands-on scale-up support is agreed during consultation and depends on the process and equipment involved.
Turnaround depends on the number of formulations screened, the assays involved, and payload availability. Please contact our team for a timeline specific to your program.

Scientific Literature

References

Pozdniakova N, Generalov E, Shevelev A, Tarasova O. RNA Therapeutics: Delivery Problems and Solutions-A Review. Pharmaceutics. 2025;17(10):1305. View on PubMed
Won Lee J, Kyu Shim M, Kim H, et al. RNAi therapies: Expanding applications for extrahepatic diseases and overcoming delivery challenges. Advanced drug delivery reviews. 2023;201:115073. View on PubMed
Tang Y, Zou J, Li Q, et al. Small nucleic acid therapeutics: delivery breakthroughs, clinical translation, and future paradigms in precision medicine. International journal of pharmaceutics. 2025;684:126189. View on PubMed

Please kindly note that our products and services are for research use only.